Martin Delaney Collaboratories for HIV Cure Research
ID: 359663Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359663
Timeline
    Description

    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Martin Delaney Collaboratories for HIV Cure Research," aimed at advancing research strategies to control HIV replication and ultimately eradicate HIV reservoirs. This initiative seeks to foster collaborations among academic institutions, government scientists, the private sector, and community stakeholders to accelerate HIV cure research, particularly addressing the needs of children living with HIV. The estimated total program funding is $20 million, with six awards expected to be granted, and interested small businesses can reach out to Diane Lawrence, Ph.D., at diane.lawrence2@nih.gov or call 240-627-3202 for more information. Key deadlines include an estimated synopsis post date of April 21, 2026, and a close date of August 19, 2026, with awards anticipated by March 1, 2027.

    Point(s) of Contact
    Diane Lawrence, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
    (240) 627-3202
    diane.lawrence2@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) program, aimed at advancing research in the field of infectious diseases. This initiative seeks to support innovative research that elucidates mechanisms of persistence and pathogenesis of Hepatitis B, develops clinically relevant biomarkers, identifies new drug targets, and creates non-invasive diagnostics, leveraging existing clinical data and sample repositories. With an estimated total program funding of $8 million and the expectation of awarding two grants, interested small businesses should note that the application process is open, with key deadlines including an estimated synopsis close date of August 19, 2026, and an anticipated award date of March 1, 2027. For further inquiries, applicants can contact Josh Radke, Ph.D., at josh.radke@nih.gov or by phone at 301-761-6525.
    Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research." This initiative aims to support the secondary use of archived data and biospecimen collections to enhance research in maternal, pediatric, and adolescent HIV, encouraging the integration of innovative data science methods and interdisciplinary approaches. With an estimated total program funding of $1,000,000 and the expectation of awarding two grants, interested small businesses can reach out to Samantha Calabrese at samantha.calabrese@nih.gov or call 301-827-7568 for more information. Key deadlines include an estimated synopsis post date of October 1, 2025, and a closing date of January 2, 2026, with project start and award dates anticipated for July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV." This initiative aims to support research that identifies modifiable targets and mechanisms to alleviate central nervous system (CNS) complications in individuals living with HIV, leveraging patient-derived data and innovative model platforms. The program emphasizes the importance of understanding the multifactorial nature of CNS dysfunction and seeks to accelerate the development of effective interventions through clinical studies or pre-clinical models. The estimated total funding for this program is $3 million, with approximately six awards expected. Interested applicants, particularly those with expertise in systems biology and translational neurobiology, should prepare for the upcoming Notice of Funding Opportunity (NOFO), with applications anticipated to open in September 2025. For further inquiries, potential applicants can contact Vasudev R Rao at vasudev.rao@nih.gov or by phone at 301-825-3259.
    Advancing Prevention and Treatment of Bacterial STIs in HIV-affected Adolescent and Maternal Populations
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Advancing Prevention and Treatment of Bacterial STIs in HIV-affected Adolescent and Maternal Populations." This initiative aims to support research, including clinical trials, focused on bacterial sexually transmitted infections (STIs) in adolescent and maternal populations impacted by HIV, with an emphasis on diagnostic advancements, microbicidal agents, and evidence-based prevention and treatment strategies. The total estimated funding for this program is $2,000,000, with three awards expected to be granted. Interested applicants, particularly small businesses, should note that the application deadline is January 7, 2026, and they can reach out to Franklin W. Yates, MD, at franklin.yates@nih.gov or by phone at 301-827-5536 for further inquiries.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.